Phase 2 N=16 SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Obesity · Pre-diabetes
Primary: Change in Adipose Pro-inflammatory T Helper Type 1 Cell Percentages After 3 Months — -1.6 Percentage of CD3+ T cells
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=98 A Study of LY3462817 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline on the Disease Activity Score Modified to Include the 28 Diarthrodial Joint Count-High-Sensitivity C-Reactive Protein (DAS28-hsCRP) — -0.99; -1.88…
Phase 2 N=56 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Phase 2 N=45 A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)
Diabetes type1
Primary: Incidence of Treatment-emergent Adverse Events (TEAE) — 1; 6; 1; 19 Events
Phase 2 N=34 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Malignant Pleural Mesothelioma · Mesothelioma
Primary: Disease Control Rate (DCR) — 75 percentage of participants
Phase 2 N=29 Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
Breast Cancer · Triple Negative Breast Cancer
Primary: Number and Percentage of Participants With Pathologic Complete Response (pCR) Rate — 8 Participants
Phase 2 N=25 Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
Lymphangioleiomyomatosis
Primary: Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on…
Phase 2 N=139 COVID-19 Anosmia Study
Anosmia · Covid19
Primary: Change in Brief Smell Identification Test (BSIT) — 6.77; 7.20; 7.89; 7.88 score on a scale
Phase 2 N=32 Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep
Sleep Apnea, Obstructive
Primary: Duration of Obstructive Events — 22.72; 24.66 seconds
Phase 2 N=1,225 Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
SARS-CoV 2
Primary: Cumulative Number of Hospitalizations or Deaths Prior to Hospitalization — 17; 37 Participants — p=0.005
Phase 2 N=18 Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Non-Hodgkin's Lymphoma, Relapsed · Chronic Lymphoid Leukemia in Relapse · Non-Hodgkin's Lymphoma Refractory
Primary: Maximum Tolerated Dose (MTD) — NA 10^6 CAR T cells
Phase 2 N=26 Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
Mantle Cell Lymphoma · Lymphoma, Mantle Cell
Primary: Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) — 23.5…
Phase 2 N=12 A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
Dystrophic Epidermolysis Bullosa
Primary: Number of Subjects Reported at Least One Adverse Event, Safety Population — 9 Participants
Phase 2 N=60 Crossover Trial of AD109 in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Change in Hypoxic Burden (HB) Log10HB[(%*Min)/Hour] — -0.41; -0.36; -0.04; -0.06 Log10HB4%[%min/hour]
Phase 2 N=28 A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
Crohn's Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 6; 6; 7; 3 Participants